Cure My Disease

Don't miss your cure!

 Log in / Sign up

Generic diabetes pill put to the test against Brand-Name drug

NCT ID NCT07694115

Completed Disease control Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial compares a generic extended-release tablet containing empagliflozin and metformin to the brand-name Synjardy XR. Healthy adults aged 18 to 45 receive a single dose of each version in random order, and researchers measure drug levels in the blood to see if the generic works the same. The goal is to confirm bioequivalence, which could lead to a more affordable option for managing type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin and metformin extended-release tablet
What this could lead to
If the generic tablet proves equivalent, it could offer a more affordable treatment option for people with type 2 diabetes.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual diabetes control or long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

  • Veeda Clinical Research Ltd.

    Ahmedabad, Ambawadi, 380 015, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.